Haven't had much time lately? Here's what you may have missed in the last few months
New in 2015: Hairy Cell Leukaemia, Myeloproliferative Neoplasms, Thymic Epithelial Tumours, Central Venous Access, Treatment of Dyspnoea
24 Jun 2016
Trastuzumab-related cardiotoxic effects are not reduced with the concurrent use of the angiotensin II–receptor blocker candesartan versus placebo...
23 Jun 2016
Phase II trial results support further investigation into regorafenib for patients with advanced gastric adenocarcinoma
22 Jun 2016
Results from two trials shed light on use of hypofractionated radiotherapy in prostate cancer
21 Jun 2016
In an ESMO expert interview, D. Arnold elaborates the prognostic value of Immunoscore in stage I-III colon cancer and the results of phase II study...
21 Jun 2016
The addition of zoledronate to preoperative chemotherapy fails to boost treatment-naïve osteosarcoma survival
In an ESMO expert interview, D. Arnold elaborates the prognostic value of Immunoscore in stage I-III colon cancer and the results of phase II study of nivolumab in refractory anal cancer, as presented at ASCO 2016 Annual Meeting. He says that he will be surprised if checkpoint inhibitors don’t find place soon in therapeutic algorithm of gastrointestinal malignancies.